ALDOA lactylation at the K230 and K322 sites causes DDX17 release from ALDOA, allowing DDX17 entry into the nucleus and binding to SRY-box transcription factor 2 (SOX2) to activate their target genes to maintain cancer cell stemness. Here, DDX17 is linked to cancer.